Limits...
Serum adiponectin concentration in 2,939 Japanese men undergoing screening for prostate cancer.

Ikeda A, Nakagawa T, Kawai K, Onozawa M, Hayashi T, Matsushita Y, Tsutsumi M, Kojima T, Miyazaki J, Nishiyama H - Prostate Int (2015)

Bottom Line: The adiponectin levels were significantly and negatively correlated with BMI (r =  -0.260, P < 0.0001).However, a significant and positive correlation was observed between adiponectin levels and PSA levels (r = 0.054, P = 0.0061).There was a significant positive correlation between adiponectin levels and PSA levels.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Hitachi General Hospital, Ibaraki, Japan ; Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

ABSTRACT

Background: Recent investigations suggest that serum adiponectin levels are negatively associated with the development of aggressive prostate cancer, however, not all epigenetic studies support the inverse association.

Methods: We analyzed serum adiponectin levels, prostate-specific antigen (PSA) levels, and outcomes of prostate cancer screening of 2,939 participants of a PSA-based screening program conducted by a single institute in Japan.

Results: The median body mass index (BMI) of the participants was 23.9 kg/m(2), and 31% had a BMI ≥ 25 kg/m(2). The adiponectin levels were significantly and negatively correlated with BMI (r =  -0.260, P < 0.0001). However, a significant and positive correlation was observed between adiponectin levels and PSA levels (r = 0.054, P = 0.0061). After screening, 24 (0.82%) patients were diagnosed with prostate cancer. Interestingly, the adiponectin levels of the 24 prostate cancer patients (average 9.86 μg/mL) were significantly higher than those of the 2,817 participants with PSA levels < 4 ng/mL (average 7.63 μg/mL) (P = 0.0049). However, when restricted to the eight high-risk prostate cancer patients, the adiponectin levels did not differ from those of the participants with PSA levels < 4 ng/mL. The age-adjusted cancer detection rate of the participants was calculated by stratifying the BMI (cut-off level 25 kg/m(2)) and adiponectin levels (cut-off level 6.7 μg/mL). The cancer detection rate in the high-BMI and high-adiponectin group was 1.67%, which was the highest among all groups.

Conclusions: There was a significant positive correlation between adiponectin levels and PSA levels. The present findings also suggest that the incidence of low- or intermediate-risk prostate cancer might be increased in overweight men with high serum adiponectin levels.

No MeSH data available.


Related in: MedlinePlus

Distribution of adiponectin (APN) levels according to the outcomes of the prostate cancer (PCA) screening. The APN levels in the PCA patients were significantly higher than those of the participants with prostate-specific antigen levels < 4 ng/mL, however, when restricted to the high-risk PCA patients, the APN levels did not differ from those of the participants with prostate-specific antigen levels < 4 ng/mL. PSA, prostate-specific antigen.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4588391&req=5

fig3: Distribution of adiponectin (APN) levels according to the outcomes of the prostate cancer (PCA) screening. The APN levels in the PCA patients were significantly higher than those of the participants with prostate-specific antigen levels < 4 ng/mL, however, when restricted to the high-risk PCA patients, the APN levels did not differ from those of the participants with prostate-specific antigen levels < 4 ng/mL. PSA, prostate-specific antigen.

Mentions: The APN levels of PCA patients (average 9.96 ng/mL) were significantly higher than nonprostate cancer participants (average 7.64 ng/mL; P < 0.001). Fig. 3 shows the distribution of APN levels according to outcomes of the PCA screening program. We compared the APN levels of the PCA patients with those of the participants with PSA levels < 4 ng/mL and the participants who had PSA levels ≥ 4 ng/mL but were not diagnosed with PCA. As shown in Fig. 3, the APN levels in PCA patients (average 9.86 μg/mL) were significantly higher than those of the participants with PSA levels < 4 ng/mL (average 7.63 μg/mL; P = 0.0049).


Serum adiponectin concentration in 2,939 Japanese men undergoing screening for prostate cancer.

Ikeda A, Nakagawa T, Kawai K, Onozawa M, Hayashi T, Matsushita Y, Tsutsumi M, Kojima T, Miyazaki J, Nishiyama H - Prostate Int (2015)

Distribution of adiponectin (APN) levels according to the outcomes of the prostate cancer (PCA) screening. The APN levels in the PCA patients were significantly higher than those of the participants with prostate-specific antigen levels < 4 ng/mL, however, when restricted to the high-risk PCA patients, the APN levels did not differ from those of the participants with prostate-specific antigen levels < 4 ng/mL. PSA, prostate-specific antigen.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4588391&req=5

fig3: Distribution of adiponectin (APN) levels according to the outcomes of the prostate cancer (PCA) screening. The APN levels in the PCA patients were significantly higher than those of the participants with prostate-specific antigen levels < 4 ng/mL, however, when restricted to the high-risk PCA patients, the APN levels did not differ from those of the participants with prostate-specific antigen levels < 4 ng/mL. PSA, prostate-specific antigen.
Mentions: The APN levels of PCA patients (average 9.96 ng/mL) were significantly higher than nonprostate cancer participants (average 7.64 ng/mL; P < 0.001). Fig. 3 shows the distribution of APN levels according to outcomes of the PCA screening program. We compared the APN levels of the PCA patients with those of the participants with PSA levels < 4 ng/mL and the participants who had PSA levels ≥ 4 ng/mL but were not diagnosed with PCA. As shown in Fig. 3, the APN levels in PCA patients (average 9.86 μg/mL) were significantly higher than those of the participants with PSA levels < 4 ng/mL (average 7.63 μg/mL; P = 0.0049).

Bottom Line: The adiponectin levels were significantly and negatively correlated with BMI (r =  -0.260, P < 0.0001).However, a significant and positive correlation was observed between adiponectin levels and PSA levels (r = 0.054, P = 0.0061).There was a significant positive correlation between adiponectin levels and PSA levels.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Hitachi General Hospital, Ibaraki, Japan ; Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

ABSTRACT

Background: Recent investigations suggest that serum adiponectin levels are negatively associated with the development of aggressive prostate cancer, however, not all epigenetic studies support the inverse association.

Methods: We analyzed serum adiponectin levels, prostate-specific antigen (PSA) levels, and outcomes of prostate cancer screening of 2,939 participants of a PSA-based screening program conducted by a single institute in Japan.

Results: The median body mass index (BMI) of the participants was 23.9 kg/m(2), and 31% had a BMI ≥ 25 kg/m(2). The adiponectin levels were significantly and negatively correlated with BMI (r =  -0.260, P < 0.0001). However, a significant and positive correlation was observed between adiponectin levels and PSA levels (r = 0.054, P = 0.0061). After screening, 24 (0.82%) patients were diagnosed with prostate cancer. Interestingly, the adiponectin levels of the 24 prostate cancer patients (average 9.86 μg/mL) were significantly higher than those of the 2,817 participants with PSA levels < 4 ng/mL (average 7.63 μg/mL) (P = 0.0049). However, when restricted to the eight high-risk prostate cancer patients, the adiponectin levels did not differ from those of the participants with PSA levels < 4 ng/mL. The age-adjusted cancer detection rate of the participants was calculated by stratifying the BMI (cut-off level 25 kg/m(2)) and adiponectin levels (cut-off level 6.7 μg/mL). The cancer detection rate in the high-BMI and high-adiponectin group was 1.67%, which was the highest among all groups.

Conclusions: There was a significant positive correlation between adiponectin levels and PSA levels. The present findings also suggest that the incidence of low- or intermediate-risk prostate cancer might be increased in overweight men with high serum adiponectin levels.

No MeSH data available.


Related in: MedlinePlus